Isolation of anti-HIV-1 lignans from Larrea tridentata by counter-current chromatography. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Isolation of anti-HIV-1 lignans from Larrea tridentata by counter-current chromatography.

J Chromatogr A. 1996 Jan 8;719(2):353-64. Unique Identifier : AIDSLINE MED/96155178
Gnabre JN; Ito Y; Ma Y; Huang RC; Department of Biology, Johns Hopkins University, Baltimore, MD; 21218-2685, USA.

Abstract: Several lignans, mostly new, were isolated from Larrea tridentata by assay-guided counter-current chromatography (CCC). Using the secreted alkaline phosphatase bioassay of HIV Tat transactivation and the two-phase hexane-ethyl acetate-methanol-water solvent system, two major components (Gr and Lo) were identified as anti-HIV active principles. The chemical structures of the constituents of Gr (G1-G4) and Lo (L1-L4) were determined by GC-MS and NMR. After optimization of isolation conditions, a large-scale isolation with the chloroform-methanol-water system yielded five constituents (FB1-FB5). The most predominant anti-HIV compound FB2 (denoted Malachi 4:5-6 or mal.4), which occurs in 0.23% yield, was separated from its FB1 isomer (0.13% yield). Compound FB4 and two tricyclic lignans (FB3 and FB5) were also isolated in a substantial amount for further testing of their anti-HIV activities. These compounds may represent a new class of anti-HIV agents with important clinical relevance.
Keywords: Antiviral Agents/*ISOLATION & PURIF/PHARMACOLOGY Chromatography, Thin Layer/*METHODS Gene Products, tat/PHYSIOLOGY HIV-1/*DRUG EFFECTS Lignans/*ISOLATION & PURIF/PHARMACOLOGY Mass Fragmentography Nuclear Magnetic Resonance Pilot Projects Plants, Medicinal/*CHEMISTRY Support, Non-U.S. Gov't Support, U.S. Gov't, Non-P.H.S. Support, U.S. Gov't, P.H.S. Trans-Activation (Genetics)/PHYSIOLOGY JOURNAL ARTICLEKWDantiviralagents/KWDisolation&purif/pharmacologychromatography,thinlayer/KWDmethodsgeneproducts,tat/physiologyhiv-1/KWDdrugeffectslignans/KWDisolation&purif/pharmacologymassfragmentographynuclearmagneticresonancepilotprojectsplants,medicinal/KWDchemistrysupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,non-pKWDhKWDsKWDsupport,uKWDsKWDgov't,pKWDhKWDsKWDtrans-activation(genetics)/physiologyjournalarticle
960530
M9650326

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .